← All indications
Carcinoma, Merkel Cell
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Drugs by status
Approved for this indication (2)
Phase 3 trials (4)
Phase 2 trials (63)
- Domatinostat
- antineoplaston a10
- autologous tumor infiltrating lymphocytes
- cmp-001
- prednisone
- durvalumab
- f16il2
- paclitaxel
- aldesleukin
- interleukin-12 dna
- l19il2
- lenvatinib
- mcpyv tag-specific polyclonal autologous cd8-positive t cells
- regorafenib
- phenylacetic acid
- plinabulin
- lanreotide
- carboplatin
- sapanisertib
- sirolimus
- cyclophosphamide
- temozolomide
- bevacizumab
- talimogene laherparepvec
- tremelimumab
- cabozantinib
- etbx-051
- etbx-061
- nk-92
- fludarabine
- +33 more
Phase 1 trials (30)
- allogeneic natural killer cells
- cdx-301
- cixutumumab
- tacrolimus
- imiquimod
- octreotide
- personalized neoantigen vaccine
- trastuzumab emtansine
- everolimus
- gla-se
- topotecan
- tti-621
- veliparib
- capecitabine
- sargramostim
- rp1
- cosibelimab
- incb099318
- ifx-hu2.0
- so-c101
- incb099280
- gen-011
- cdx-1140
- mem-288
- zimberelimab
- iti-3000
- crd3874
- mq719
- ph-762
- vet3-tgi
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (54)
- 4SC AG
- Incyte
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- Merck Serono
- Exelixis
- Genentech
- MedImmune
- Merck KGaA
- Exicure, Inc.
- Nanobiotix
- NantCell, Inc.
- NantWorks
- Nektar Therapeutics
- OncoSec Medical Incorporated
- Philogen S.p.A.
- immatics Biotechnologies GmbH
- University of Pittsburgh
- Medical University of Graz
- Burzynski Research Institute
- Cornell University
- Harvard University
- Ludwig Institute for Cancer Research
- Rutgers University
- Southwest Oncology Group
- Stanford University
- University of South Florida
- University of Southern California
- University of Sydney
- +24 more
Organization Involved with Phase 1 Indications (18)